Evidence for Ketamine in Cocaine Use Disorder
The evidence for ketamine in treating cocaine use disorder is promising but preliminary, showing short-term efficacy in reducing cocaine use and craving when combined with psychotherapy, though it remains investigational and is not FDA-approved for this indication.
Current Evidence Base
The available research demonstrates encouraging signals for ketamine's utility in cocaine use disorder, though the evidence remains limited in scope and quality. A single ketamine infusion (0.5 mg/kg IV over 40 minutes) combined with mindfulness-based relapse prevention showed that 48.2% of patients maintained abstinence over the final 2 weeks of treatment compared to 10.7% in the midazolam control group 1. This represents a 53% reduction in relapse risk and a 58% reduction in craving scores throughout the trial 1.
Laboratory studies corroborate these clinical findings. In a controlled self-administration paradigm, ketamine decreased cocaine self-administration by 67% relative to baseline at >24 hours post-infusion—the most robust reduction observed to date in human cocaine users 2. This effect appears to involve mechanisms distinct from traditional stimulant or dopamine agonist approaches 2.
Mechanism of Action
Ketamine's therapeutic effects in cocaine use disorder likely stem from its NMDA receptor antagonism and downstream effects on glutamatergic neurotransmission. The drug directly targets multiple genes implicated in cocaine dependence (BDNF, CNR1, DRD2, OPRM1, SLC6A3) and pathways involved in neuroactive ligand-receptor interaction and cAMP signaling 3. This glutamatergic modulation may disrupt maladaptive reward-related memories and reverse neuroadaptations that maintain addiction 4, 5.
Duration of Effect and Limitations
The primary limitation is that ketamine's efficacy appears time-limited. Meta-analytic evidence shows significant improvement in abstinence at <1 month (OR = 3.27,95% CI: 1.55-6.92) but not at 1-6 months (OR = 1.74,95% CI: 0.91-3.30) 6. This suggests ketamine may be most useful as an adjunctive intervention to facilitate engagement with psychotherapy rather than as a standalone treatment 7.
Safety Considerations
Critical FDA-Labeled Warnings
The FDA label for ketamine includes several warnings highly relevant to substance use disorder populations 8:
- Drug-induced liver injury with recurrent use, particularly concerning given the need for repeated dosing in addiction treatment
- Psychiatric adverse events that may persist days to weeks after exposure
- Lower urinary tract symptoms with chronic use (dysuria, frequency, urgency, hematuria)
- Abuse liability: Ketamine itself carries misuse potential, creating a paradox when treating addiction 5
- Respiratory depression when combined with other CNS depressants, including alcohol and opioids—common co-occurring substances in cocaine use disorder
Clinical Context
The abuse liability concern is particularly salient. While ketamine shows promise for treating cocaine dependence, it is itself a drug of abuse with established addiction potential 5. This necessitates careful patient selection, excluding those with active polysubstance use disorders involving dissociative agents, and mandating supervised administration in controlled clinical settings 4.
Current Clinical Recommendations
Ketamine should only be considered for cocaine use disorder within research protocols or highly specialized addiction treatment programs with appropriate monitoring infrastructure. The intervention requires:
- Supervised IV administration (0.5 mg/kg over 40 minutes)
- Integration with evidence-based psychotherapy (mindfulness-based relapse prevention or cognitive behavioral therapy)
- Baseline liver function tests and periodic monitoring with repeated dosing 8
- Exclusion of patients with active polysubstance dependence, particularly involving other dissociatives
- Continuous monitoring during and after infusion for hemodynamic instability and emergence reactions 8
Comparison to Established Treatments
For cocaine use disorder, contingency management plus community reinforcement approach remains the evidence-based first-line treatment 9. International guidelines recommend psychosocial interventions as primary treatment, with no approved pharmacotherapies 9. A comprehensive network meta-analysis found no convincing evidence for the effectiveness of any pharmacological treatments for cocaine use disorder, including ketamine 10.
Critical Gaps
The evidence base suffers from:
- Small sample sizes (largest trial: n=55)
- Short follow-up periods
- Homogeneous populations limiting generalizability
- Variability in dosing strategies and comparator conditions
- Insufficient long-term safety data 7, 6
Larger-scale Phase 3 trials with extended follow-up are essential before ketamine can be recommended outside research settings for cocaine use disorder 4, 5. Until such data emerge, clinicians should prioritize established psychosocial interventions while considering ketamine only within approved research protocols.